NCT04616534View on ClinicalTrials.gov

Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

April 1, 2025

Study Completion Date

May 20, 2026

Conditions
Advanced Fallopian Tube CarcinomaAdvanced Malignant Solid NeoplasmAdvanced Ovarian CarcinomaAdvanced Pancreatic AdenocarcinomaAdvanced Primary Peritoneal CarcinomaFallopian Tube High Grade Serous AdenocarcinomaMetastatic Pancreatic AdenocarcinomaOvarian High Grade Serous AdenocarcinomaPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaPrimary Peritoneal High Grade Serous AdenocarcinomaStage II Pancreatic Cancer AJCC v8Stage III Fallopian Tube Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage III Primary Peritoneal Cancer AJCC v8Stage IV Fallopian Tube Cancer AJCC v8Stage IV Ovarian Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Stage IV Primary Peritoneal Cancer AJCC v8Unresectable Pancreatic Adenocarcinoma
Interventions
PROCEDURE

Biopsy Procedure

Undergo biopsy (dose expansion cohort only)

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

Diagnostic Imaging Testing

Undergo medical imaging scans

DRUG

Elimusertib

Given PO

DRUG

Gemcitabine

Given IV

Trial Locations (3)

20892

National Cancer Institute Developmental Therapeutics Clinic, Bethesda

National Institutes of Health Clinical Center, Bethesda

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH